Skip to Content


Active Substance: eslicarbazepine acetate
Common Name: eslicarbazepine acetate
ATC Code: N03AF04
Marketing Authorisation Holder: BIAL - Portela & Ca, S.A.
Active Substance: eslicarbazepine acetate
Status: Withdrawn
Authorisation Date: 2009-04-21
Therapeutic Area: Epilepsy
Pharmacotherapeutic Group: Antiepileptics

Therapeutic Indication

Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.

The marketing authorisation for for Exalief has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.